BRIEF—Novo Nordisk ABPI membership restored

Denmark-based Novo Nordisk’s two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for serious breaches of the ABPI Code of Practice has come to an end.
 Novo Nordisk’s return to full membership of the ABPI follows extensive audits of Novo Nordisk’s compliance procedures and governance by the Prescription Medicines Code of Practice Authority (PMCPA). Specifics of the original case are available on the PMCPA website.
Novo Nordisk, supported by the independent PMCPA audit reports, has demonstrated to the ABPI Board’s satisfaction that the company has made clear, significant, and sustained improvements to ensure it is able to properly adhere to the strict industry standards in the ABPI Code of Practice, the trade group said.